Maze Therapeutics SEC Filings

Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 2,625,089 shares of Maze Therapeutics common stock, representing 6.0% of the outstanding class. The filing shows no sole voting or dispositive power and discloses shared voting and dispositive power over those shares, indicating the position is managed collectively rather than controlled by a single entity. The reporting person is classified as an investment adviser (IA, HC), and the filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.

The filing further identifies indirect subsidiaries as the operating vehicles that acquired the securities and includes a power of attorney authorizing firm personnel to file ownership reports on the company’s behalf.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report joint beneficial ownership of 3,948,910 shares of Maze Therapeutics common stock, which the statement says represents 9.02% of the outstanding common shares. The holders report shared voting and shared dispositive power over those shares and no sole voting or dispositive power.

The ownership percentage is calculated from 43,797,166 shares outstanding per the issuer's public disclosures. The filing includes a certification that the shares were not acquired to change or influence control of the issuer and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.

Maze Therapeutics reported widening operating losses as it advances clinical programs while strengthening its balance sheet through an IPO and earlier licensing deals. For the quarter ended June 30, 2025 the company recorded a net loss of $33.7 million and a six‑month loss of $66.5 million, driven by higher research and development and public‑company costs. Research and development expense rose to $28.1 million for the quarter from $19.5 million a year earlier, reflecting clinical and manufacturing progression of lead programs.

The company completed an initial public offering that generated net proceeds of approximately $127.8 million, and held $264.5 million in cash and cash equivalents as of June 30, 2025, which management says is sufficient to fund operations for at least one year. In 2024 Maze recognized $165.0 million of license revenue from three agreements, including a $150.0 million upfront from Shionogi. The balance sheet now reflects elimination of redeemable convertible preferred stock after conversion to common shares. Overall, Maze is a clinical‑stage biotech investing heavily in R&D with one year of disclosed liquidity and no product revenue from sales.

Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.